A new study indicates significant therapeutic potential in Alzheimer's disease using new drugs that clear beta-amyloid protein from the brain.
The drugs, Donanemab and Lecanemab, have shown significant success in phase 3 of clinical trials, and may lead to a significant change in the way the disease is treated.
What is Alzheimer's disease?
Alzheimer's disease is a degenerative disease that affects the brain and causes a progressive decline in memory, cognition and other functions.
The main feature of the disease is the accumulation of an abnormal protein called beta-amyloid in the brain.
How do the new drugs work?
Donanumab and lecanumab are monoclonal antibodies directed against beta-amyloid protein.
They work by binding to a protein and breaking it down from the brain.
Results of clinical trials
Phase 3 clinical trials showed that donanumab and lanumab were able to significantly reduce beta-amyloid protein levels in the brains of patients with mild to moderate Alzheimer's.
In addition, a slowdown in the rate of cognitive decline was observed in patients treated with these drugs.
Additional therapeutic effects
Studies show that clearing beta-amyloid protein from the brain may lead to additional therapeutic effects, such as:
- improving memory function
- Improving thinking ability
- Slowing down the decline in daily abilities
- Improving the quality of life
Additional detail:
- Donanumab and Lacanumab are biological drugs called monoclonal antibodies.
- They are given by intravenous infusion.
- These treatments are not yet available to the general public, and can only be obtained as part of clinical trials or special access programs.
- Possible side effects include headaches, nausea, fatigue and allergic reactions.
- More serious side effects, but rare, include brain bleeding and brain swelling.
- Further studies are required to evaluate the effectiveness and safety of donanumab and lacanumab over time.
- These studies will also examine the effect of the treatment on the quality of life of Alzheimer's patients.
The importance of the breakthrough
The breakthrough in the treatment of Alzheimer's disease using donanumab and kanumab is of great importance, as it offers for the first time an effective treatment in reducing the accumulation of beta-amyloid protein in the brain.
However, it is important to note that:
- These drugs do not cure Alzheimer's disease.
- They may slow the progression of the disease and improve the quality of life of patients.
- Further studies are required to understand the long-term effects of the treatment.
